Video

Dr. Finn on PD 0332991 Plus Letrozole in Breast Cancer

Richard Finn, MD, from the Jonsson Comprehensive Cancer Center, describes results from a phase II study that examined PD 0332991 in combination with letrozole for women with metastatic ER-positive breast cancer.

Richard Finn, MD, Division of Hematology/Oncology at the Jonsson Comprehensive Cancer Center, University of California, Los Angeles, describes results from a phase II study that examined PD 0332991, an oral selective inhibitor of cyclin-dependent kinase 4/6, in combination with letrozole as a treatment for postmenopausal women with metastatic ER-positive breast cancer.

In the trial, 165 patients were randomized 1:1 to receive letrozole alone or in combination with PD 0332991. Patients were further stratified into two parts based on molecular characteristics. Part 2 of the study contained patients with CCND1 amplification and/or a loss of p16 expression.

Finn explains that the addition of PD 0332991 to letrozole resulted in a dramatic improvement between all subgroups of the trial. The median progression-free survival (PFS) benefit for the combination was 26.1 months compared to 7.5 months for letrozole alone (HR = 0.37; P < .001).

A phase III trial is planned to begin in 2013 to further examine the efficacy of PD 0332991 in breast cancer.

<<<

View coverage from the 2012 SABCS

Related Videos
Joyce A. O’Shaughnessy, MD, and Neil M. Iyengar, MD
Joyce A. O’Shaughnessy, MD, and Neil M. Iyengar, MD
Joyce A. O’Shaughnessy, MD, and Neil M. Iyengar, MD
Joyce A. O’Shaughnessy, MD, and Neil M. Iyengar, MD
Joyce A. O’Shaughnessy, MD, and Neil M. Iyengar, MD
Toni K. Choueiri, MD
Neil J. Shah, MBBS
Andrew Davis, MD
Video 6 - 2 KOLs are featured in, "Other trials of note investigating targeted therapies in later line HR+/HER2- mBC"
Video 5 - 2 KOLs are featured in, "Targeted Therapies in HR+/HER2- mBC: CAPItello-291"